Spero licenses Innovent’s experimental immune disease drug for up to $1.1 billion

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

Spero Therapeutics has licensed rights outside Greater China to develop and commercialize Innovent Biologics' ​experimental autoimmune disease treatment in a deal worth ‌up to about $1.1 billion, the companies said on Tuesday.

Spero inks $105M financing deal with KKR affiliate (SPRO:NASDAQ)

Spero inks $105M financing deal with KKR affiliate

Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future...

Innovent licenses IBI355 rights to Spero for up to $1.1bn

Innovent Biologics has granted Spero Therapeutics an exclusive licence deal to develop and commercialise IBI355 outside Greater China.The post Innovent licenses IBI355 rights to Spero for up to $1.1bn appeared first on Hospital Management.

In latest deal, Innovent seeds Spero's future beyond GSK-owned antibiotic

After partnering with four of the largest pharmaceutical companies over the past 18 months, Innovent Biologics is turning to a smaller partner for its next bet. An autoimmune drug candidate from the Suzhou, China-based biopharma ...